

**HAIYAN FU, PHD, PRINCIPAL INVESTIGATOR, CENTER FOR GENE THERAPY,  
THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL**

**PUBLICATIONS**

1. Duncan FJ, Naughton BJ, Zaraspe K, Murrey DA, Meadows AS, Newsome DE, White P, Fu H, McCarty DM (2015) Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice. *Mol Ther* 23(4):638-47. DIO: 10.1111/php.12441
2. Naughton BJ, Duncan FJ, Murrey DA, Meadows AS, Newsom DE, Stoicea N, White P, Scharre DW, McCarty DM, **Fu H** (2015) Blood genome-wide transcriptional profiles reflect broad molecular impairments and strong blood-brain links in Alzheimer's disease. *J Alzheimer's Dis* 43(1):93-108, DOI: 10.3233/JAD-140606
3. Murrey DA, Naughton BJ, Duncan FJ, Meadows AS, Ware TA, Campbell KJ, Bremer WG, Walker CM, Goodchild L, Bolon B, la Perie K, Flanigan KM, McBride KL, McCarty DM, **Fu H** (2014) Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and Immunological Assessments in Primates. *Hum Gene Ther Clin Dev* 25(2):72-84.
4. McCarty DM, **Fu H** (2014) Gene therapy for neurodevelopmental disorders. *eLS*, John Wiley & Sons, Ltd (DOI: 10.1002/9780470015902.a0025276).
5. Naughton BJ, Duncan FJ, Murrey D, Ware T, Meadows A, Mccarty DM, **Fu H** (2013). Amyloidosis, Synucleinopathy, and Prion Encephalopathy in a Neuropathic Lysosomal Storage Disease: the CNS-biomarker Potential of Peripheral Blood. *PLoS One*, 2013. **8**(11): p. e80142.
6. **Fu H**, McCarty DM (2013) Treating Lysosomal Storage Diseases that Affect the Central Nervous System: Overcoming the Blood-brain Barrier. *Current Medical Literature – LSD*, 11(2):33-41
7. Rosas LE, Grieves JL, Zaraspe K, La Perle KM, **Fu H**, McCarty DM (2012) Patterns of scAAV Vector Insertion Associated With Oncogenic Events in a Mouse Model for Genotoxicity. *Mol Ther*. Doi: 10.1038/mt.2012.197
8. **Fu H**, Bartz JD, Stephens RL Jr, McCarty DM (2012) Peripheral Nervous System Neuropathology and Progressive Sensory Impairments in a Mouse Model of Mucopolysaccharidosis IIIB. *PLoS ONE* 7(9): e45992. DOI:10.1371/journal.pone.0045992
9. **H. Fu**, J. DiRosario, S. Killedar, K. Zaraspe, DM. McCarty (2011) Correction of Neurological Disease of Mucopolysaccharidosis IIIB in Adult Mice by Trans-Blood-Brain-Barrier Gene Delivery. *Mol Ther* 19(6):1025-33
10. DM McCarty, J DiRosario, K Gulaid, S Killedar, A Oosterhof, TH van Kuppevelt, PT Martin, **H Fu** (2011) Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice. *Metab Brain Dis*. 26(1):9-19
11. S. Killedar, J. DiRosario, E. Divers, PG. Popovich, DM. McCarty, **H. Fu** (2010) Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response. *J Neuroinflammation* July 16, 7(39)(DOI: 1742-2094-7-39)
12. **H Fu**, J DiRosario, L Kang, J Muenzer, DM McCarty (2010) Restoration of CNS  $\alpha$ -N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal rAAV2 vector delivery. *J Gene Med*, 12(7):624-33.
13. DM McCarty, J DiRosario, K Gulaid, J Muenzer, **H Fu** (2009) Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. *Gene Therapy* 16(11):1340-52

**HAIYAN FU, PHD, PRINCIPAL INVESTIGATOR, CENTER FOR GENE THERAPY,  
THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL**

14. J DiRosario, E Divers, C Wang, A Charrier, P Jukkola, J Etter, H Auer, V Best, DL Newsom, DM McCarty, **H Fu** (2009) Innate and adaptive immune activation in the brain of MPS IIIB mouse model. *J. Neuroscience Res*, 87(4):978-990
15. **H Fu**, L Kang, JS Jennings, SS Moy, A Perez, J DiRosario, DM McCarty, J Muenzer (2007) Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult Mucopolysaccharidosis IIIB mice. *Gene Therapy*, 14:1065-1077.  
(corresponding author: **Fu**)
16. **H Fu**, J Muenzer, RJ Samulski, G Breese, J Sifford, X Zeng, DM McCarty (2003) self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene eExpression in mouse brain. *Mol. Therapy*. 8(6):911-7
17. DM. McCarty, **H Fu**, PE Monahan, CE Tolson, P Naik, RJ Samulski. (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome rate-limiting step to transduction *in vivo*. *Gene Therapy*, 10(26):2112-8.
18. **H Fu**, R.J Samulski, TJ McCown, J Picornell, D Fletcher, J Muenzer (2002) Neurological correction of lysosomal storage in mucopolysaccharidosis IIIB knock-out mouse model by adeno-associated virus-mediated gene delivery. *Mol. Therapy*. 5(1):42-9
19. **H Fu**, CJ Leake, PPC Mertens, PS Mellor (1999) The barriers to bluetongue virus infection, dissemination and transmission in the vector, *Culicoides variipennis* (Diptera:Ceratopogonidae). *Arch. Virol.* 144:747-61
20. ZT Kelleher, **H Fu**, E Livanos, B Wendelburg, S Gulino, J-M Vos (1998) First-generation of mouse artificial episomal chromosomes for shuttling 100 kb of self-replicating human DNA. *Nature Biotechnology*. 16(8):762-8.
21. LA Martin, AJ Meyer, RS O'Hara, **H Fu**, PS Mellor, NJ Knowles, PPC Mertens (1998) Phylogenetic analysis of African horse sickness virus segment 10: sequence variation, virulence characteristics and cell exit. *Arch. Virol-Supplementum*. 14:281-93
22. PP Mertens, JN Burroughs, A Walton, MP Wellby, **H Fu**, RS O'Hara, SM Brookes, PS Mellor (1996) Enhanced infectivity of modified bluetongue virus particles for two insect cell lines and for two *Culicoides* vector species. *Virology*. 217(2) 582-93
23. **H Fu**, R Cai, M Jia (1991) The distribution of serotypes and biotypes of *Campylobacter jejuni/coli* isolated from ten provinces/cities in China. *Chinese J Epidemiol*. 1:25-28
24. **H. Fu** (1987) *Campylobacter* and Guillain-Barr syndrome *Chinese Zoonosis*